FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 08/2024”. The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of August 2024 we identified the following current VC trends in Europe:
- Total Healthcare & Life Sciences funding reached EUR 5,581m
- Biotech received 58% of the total investment volume (EUR 3,218m) with oncology being the leading indication (48%)
- August saw very little VC activity in Europe (EUR 133m) with Healx (United Kingdom) securing the highest transaction volume with EUR 43m, followed by Hexarad (United Kingdom) with EUR 13m and Vandria (Switzerland) with EUR 11m
- General Atlantic (United States) is the most active investor (by deal volume), followed by European Innovation Council Fund (Belgium) and Forbion (Netherlands)
To access the full report, please click here.